Actelion slips, DNA gains after positive panel

Actelion (SWX:ATLN) was off CHF1 to CHF50, while partner Genentech was up $1.14 to $43.20 on Monday following a positive panel vote last Friday by the FDA's Cardiovascular and Renal Drugs Advisory Com...